IDO1 and melanoma: Preclinical data indicate the synergism of IDO and immune checkpoint inhibitors in reducing the growth of the tumor, thereby offering a promising therapeutic strategy for melanoma, especially considering the fact that the use of IDO-blocking agents has not been associated with high toxicity [69,73].